funding availability

Whether the company can raise money when it needs it, by equity, debt or refinancing, and on what terms.

Exposure · 55 companies

Show
8-K events
Match any selected event
8-K event types
More events

Only filters 8-Ks. Other selected forms stay visible.

  • ADBT Advasa Holdings, Inc.

    Exposed“Their renewal, replacement, expansion and pricing are uncertain; market disruption, higher rates, inflation, regulation or industry developments could reduce availability or increase costs.”

    Latest 424B4final IPO prospectusAccounting issueCustomer concentrationControlled company ·

    Japanese earned-wage-access platform FUKUPE depends on one customer for 93.6% of FY2026 revenue

  • AME Ametek

    Exposed“financing access”

    Latest 8-KDebt financing ·

    Senior note offerings in U.S. and Canadian dollars and €1.5B in euros will fund debt repayment and general corporate purposes.

  • APMD Apnimed, Inc.

    Exposed“APMD expects significant losses to continue and says there is substantial doubt about its ability to continue as a going concern.”

    Latest 424B4final IPO prospectusBankruptcy / going concernAccounting issueCEO/CFO change ·

    Develops Oxnimbi, a once-nightly sleep apnea pill; $192M all-primary raise funds regulatory work and launch if approved.

  • ARCC ARES CAPITAL CORP

    Exposed“These conditions have materially affected—and could continue to affect—portfolio values and the company’s ability to raise or deploy capital.”

    Latest 10-QQ3 FY2026 ·

    MFIC acquisition would expand the portfolio as lower lending yields pressure income and investment markdowns erode NAV.

    • Total investment income$763.0MYoY −2.4%
    • Net income$319.0MYoY −21.0%
  • ARMP Armata Pharmaceuticals, Inc.

    Exposed“The company needs substantial additional capital to operate and develop products; financing may be unavailable or offered only on unfavorable terms.”

    Latest 10-QQ3 FY2026NegativeBankruptcy / going concern ·

    AP-SA02 advances toward Phase 3 with FDA support and expanded MTEC funding, but a cash shortfall threatens development.

    • Revenue$3.2MYoY +173.6%
    • Net income$54.9Mvs −$26.7M year ago
  • ASPE Aspen Neuroscience, Inc.

    Exposed“Additional capital will be needed; unavailable or unfavorable financing could dilute shareholders, impose restrictive terms, require relinquishing valuable rights, or force delays, reductions or termination of programs.”

    Latest 424B4final IPO prospectusBankruptcy / going concernPre-revenue ·

    Develops patient-derived Parkinson’s cell therapy; $141M all-primary raise backs sasineprocel’s move toward Phase 3

  • BBTX Bambusa Therapeutics, Inc.

    Exposed“Management concluded there is substantial doubt about the company’s ability to continue as a going concern for the 12 months after the audited financial statements were available to be issued.”

    Latest 424B4final IPO prospectusPositiveBankruptcy / going concernAccounting issueImpairment / charge ·

    Develops dual-target antibodies for eczema and respiratory diseases; $169M raise funds trials of BBT001 and BBT002.

  • BE Bloom Energy Corp

    Exposed“Management expects cash and operating cash generation to cover at least 12 months of anticipated needs, but warns that future financing may be needed and could be unavailable, restrictive or dilutive.”

    Latest 10-QQ3 FY2026PositiveLegal / investigation ·

    Accelerating Energy Server deliveries and manufacturing gains drove the profit surge, with growth concentrated in two customers.

    • Revenue$1.2BYoY +138.1%
    • Net income$250.3Mvs −$23.1M year ago
  • BLSM BlossomHill Therapeutics, Inc.

    Exposed“The company expects to need substantial additional financing; unavailable or unfavorable funding could dilute stockholders or delay, reduce, or terminate development programs.”

    Latest 424B4final IPO prospectusBankruptcy / going concernPre-revenue ·

    Develops small-molecule cancer drugs; $150M all-primary raise funds trials led by BH-30643 for treatment-resistant lung cancer.

  • BRVE Braveheart Bio, Inc.

    Exposed“Financing may be unavailable, costly or dilutive, and failure to raise funds could force it to delay, reduce or terminate development, surrender rights, or cease operations.”

    Latest 424B4final IPO prospectusPositiveImpairment / chargePre-revenueRelated-party dependence ·

    Develops BHB-1893, an oral cardiac myosin inhibitor for hypertrophic cardiomyopathy; $383M all-primary raise funds Phase 3 trials.

  • BX Blackstone Group

    Exposed“Liquidity depends partly on realizations, which can be volatile, and may be pressured if weak realizations coincide with fund capital calls.”

    Latest 10-QQ3 FY2026 ·

    Lower Private Equity realizations against last year’s GP Stakes sale outweighed recurring-fee growth.

    • Revenue$3.1BYoY −0.8%
    • Net income$662.4MYoY +6.0%
  • CAPR CAPRICOR THERAPEUTICS, INC.

    Exposed“It expects to need additional capital to fund clinical trials and development programs.”

    Latest 10-QQ3 FY2026NegativeRestructuring ·

    Deramiocel’s FDA bid narrows to upper-limb impairment after an adverse cardiac efficacy vote; a Nippon Shinyaku dispute complicates launch plans.

    • Revenue$0vs $0 year ago
    • Net income−$42.7MYoY −73.6%
  • CBOE Cboe Global Markets, Inc.

    Exposed“Cboe Clear Europe also has a €1.20 billion secured facility expected to terminate within a year; replacement financing and the facility’s ability to cover clearing obligations are material liquidity risks.”

    Latest 10-QQ3 FY2026PositiveRestructuring ·

    Extended exclusive SPX rights and overseas exits sharpen the derivatives focus; Australia sale gain boosts reported profit.

    • Revenue$1.4BYoY +19.0%
    • Net income$428.2MYoY +42.4%
  • CIM CHIMERA INVESTMENT CORP

    Exposed“Much of this funding is short-term, uncommitted, and renewable at lenders’ discretion.”

    Latest 10-QQ3 FY2026Negative ·

    Mortgage valuation losses eroded capital; funding, hedging and loan-sale pricing pressures pushed HomeXpress into a loss.

    • Net interest income$71.2MYoY +9.5%
    • Net income−$172.2Mvs −$580.0K year ago
  • CRWV CoreWeave, Inc.

    Exposed“If cash flow or refinancing access is insufficient, the company may have to delay investment, sell assets, raise capital, or restructure debt.”

    Latest 10-QQ3 FY2026Accounting issue ·

    Existing customers drive AI cloud growth; Meta and OpenAI commitments require more capacity as infrastructure and interest costs deepen losses.

    • Revenue$3.7BYoY +168.2%
    • Net income−$709.0Mvs −$110.0M year ago
  • CSQR Csquare, Inc.

    Exposed“Higher interest costs, capital requirements, and continued reliance on refinancing and capital-market access remain key risks.”

    Latest 424B4final IPO prospectusMixedControlled companyProceeds to insiders or debt ·

    Sells data-center space, power and connectivity; nearly all of the $1.05B raise repays debt, with Brookfield retaining control

  • CTY CITY THERAPEUTICS, INC.

    Exposed“The company has no committed additional financing and expects losses and expenses to rise; it may need capital before the stated runway ends.”

    Latest 424B4final IPO prospectusCustomer concentration ·

    Develops RNA interference drugs led by CITY-FXI for thrombosis; raises $200M entirely through new shares.

  • CVNA Carvana

    Exposed“Management expects available sources to cover operations and commitments for at least 12 months, while longer-term debt service and growth investment depend on cash generation and continued access to financing.”

    Latest 10-QQ3 FY2026 ·

    ADESA expansion plans target retail growth as weaker loan-sale spreads and wholesale contributions squeeze gross profit per retail unit.

    • Revenue$8.0BYoY +42.4%
    • Net income$289.0MYoY +91.4%
  • EMI Encore Medical, Inc.

    Exposed“Management plans to seek additional equity financing, but availability and sufficiency are uncertain.”

    Latest S-1/Aamended IPO prospectusNegativeBankruptcy / going concernAccounting issueCustomer concentration ·

    Sells catheter-delivered devices to close holes in the heart; IPO triggers a $7M technology license outside its core business

  • ENB Enbridge

    Exposed“Enbridge identifies capital-market volatility as a potential funding constraint given its sizable growth program; it relies on operating cash flow, commercial paper, credit facilities and debt/equity offerings while seeking to preserve investment-grade ratings and diversified bank access.”

    Latest 8-KDebt financing ·

    Completed a US$1.1B offering of fixed-to-fixed subordinated notes due 2057, adding long-term debt.

  • EPD Enterprise Products

    Exposed“Investment plans depend on cash generation and access to capital, and are exposed to commodity prices, demand, customer credit, costs, labor and materials availability, weather and regulation.”

    Latest 8-KDebt financing ·

    Completed $1.5B senior-note offering to fund growth, possible acquisitions and repayment of 2027 notes and commercial paper.

  • ETRA Electra Therapeutics, Inc.

    Exposed“A funding shortfall could delay, reduce, or terminate programs.”

    Latest 424B4final IPO prospectusMixedBankruptcy / going concernPre-revenue ·

    Develops antibodies to remove disease-driving immune cells; $350M all-primary raise funds ipsoprubart’s registrational trials

  • FFPP Fast Finance Pay Corp.

    Exposed“Management states cash will not fund operations for one year after the prospectus date without additional fundraising and acknowledges substantial doubt about the company’s ability to continue as a going concern.”

    Latest S-1/Aamended IPO prospectusMixedBankruptcy / going concernControlled companyRelated-party dependence ·

    OK.de webmail ads and referral services; Jensen- and Dartsch-controlled holders retain 72% of post-offering votes.

  • GEV GE Vernova

    Exposed“A below-investment-grade downgrade was estimated to have insignificant direct liquidity impact, but could raise financing and hedging costs, impair contract awards and credit access, and increase refinancing risk.”

    Latest 10-QQ3 FY2026Positive ·

    Higher gas-turbine pricing and deliveries lift Power profitability, while Prolec GE adds transformer capacity.

    • Revenue$12.6BYoY +26.8%
    • Net income$1.3BYoY +185.6%
  • HE Hawaiian Electric Industries

    Exposed“HEI is arranging financing for remaining settlement payments, but success is not assured; below-investment-grade ratings, rebuilding needs, inflation and fuel costs add funding pressure.”

    Latest 8-KNegativeGuidanceImpairment / chargeEarnings ·

    Maui wildfire recovery plan targets financing a fixed $1.99B settlement share while limiting dilution and pursuing rate rebasing

  • IAM Iambic Therapeutics, Inc.

    Exposed“Additional capital will likely be needed; financing may dilute shareholders, impose restrictive terms, or require IAM to surrender valuable rights.”

    Latest 424B4final IPO prospectusPositivePre-revenueCustomer concentration ·

    AI-driven drug developer raises $150M to advance lead HER2 cancer candidate IAM1363 and its pipeline

  • IMC IMC Rare Earths Ltd

    Exposed“Further financing will be needed for working capital and project development, and management cautions that it may not be successful in obtaining it.”

    Latest 424B4final IPO prospectusBankruptcy / going concernAccounting issuePre-revenue ·

    Brazilian rare-earth explorer targets Itarantim’s entirely inferred resources at a $526M implied IPO valuation.

  • LIS LIS Technologies Inc

    Exposed“We will need to raise substantial additional capital through one or more financing transactions, which may include equity or debt financings, strategic investments, commercial arrangements, or other sources of capital, to implement our longer-term business plan and advance our technology toward commercialization.”

    Latest S-1/Aamended IPO prospectusNegativeBankruptcy / going concernPre-revenue ·

    Developing lab-validated CRISLA laser uranium enrichment, with commercial operations targeted around 2033

  • LTGO Latigo Biotherapeutics, Inc.

    Exposed“Financing may be unavailable, delayed, or unfavorable; equity could dilute holders, debt could impose restrictive terms, and collaborations or licenses could require surrendering valuable rights.”

    Latest 424B4final IPO prospectusPositiveBankruptcy / going concernAccounting issuePre-revenue ·

    Develops oral Nav1.8 non-opioid pain drugs; $346M all-primary raise backs LTG-001 pivotal trials and LTG-321 chronic-pain studies.

  • LYCA Lycia Therapeutics, Inc.

    Exposed“Further capital may be needed; unavailable or unfavorable financing could force delays, reductions or termination of programs.”

    Latest 424B4final IPO prospectusMixedPre-revenue ·

    Develops protein degraders for food allergy and Graves’ disease; raises $318M gross to advance clinical trials.

  • MAIN Main Street Capital Corp

    Exposed“Access to debt and equity financing may also be unavailable or unattractive when needed.”

    Latest 10-QQ3 FY2026Mixed ·

    Weaker Lower Middle Market dividends and costlier debt outweighed portfolio growth, squeezing per-share investment income.

    • Total investment income$142.5MYoY +1.9%
    • Net income$117.1MYoY −5.3%
  • MRNA Moderna

    Exposed“Moderna warns that operating cash flow may be insufficient to service debt and fund capital expenditures.”

    Latest 8-KPositiveDebt financing ·

    Credit amendment cuts initial and delayed-draw term-loan margins 75 bp and extends maturity to November 2031.

  • MSTR Strategy

    Exposed“The company expects to rely on USD cash and reserves, bitcoin sales, at-the-market (ATM) sales of common and preferred stock, and additional debt or equity financing.”

    Latest 8-KEquity raise ·

    Common-stock sales fund $206.3M of STRC preferred buybacks and $33.4M of bitcoin purchases

  • NEE NextEra Energy

    Exposed“NEE, FPL, and NEECH depend on operating cash flow and capital-market access; a downgrade could increase funding costs, restrict financing access, or trigger collateral requirements.”

    Latest 8-KImpairment / charge ·

    Pro forma disclosure values the pending Dominion acquisition at $62.1B, with more than $2.25B in planned customer bill credits.

  • NEOA Neo Aeronautics, Inc.

    Exposed“Capital may be unavailable or costly; shortfalls could force dilution, debt-service burdens, restrictions, spending cuts, delayed plans, restructuring, or curtailed or ceased operations.”

    Latest S-1/Aamended IPO prospectusNegativeBankruptcy / going concernAccounting issuePre-revenue ·

    Develops single-seat electric aircraft for Crimson flying clubs; offering funds the transition from prototypes to a targeted 2028 commercial launch.

  • NSCL Nscale plc

    Exposed“The capital-intensive model depends on continued financing.”

    Latest S-1/Aamended IPO prospectusNegativeAccounting issueCustomer concentrationRelated-party dependence ·

    Sells AI computing to Microsoft and Anthropic; its $106B active-and-contracted order portfolio depends on financing and deploying GPUs.

  • NUOX NuvOx Therapeutics, Inc.

    Exposed“Financing may be unavailable or costly: equity dilutes shareholders, debt adds repayment and covenant burdens, and collaborations may require surrendering rights or future revenue.”

    Latest S-1/Aamended IPO prospectusNegativeBankruptcy / going concernRestatementAccounting issue ·

    Intravenous oxygen drug developer seeks $20M gross at IPO midpoint to advance NanO₂ trials, with glioblastoma results the next major test

  • QMLS QumulusAI, Inc.

    Exposed“Financing may be unavailable or costly, potentially delaying expansion or requiring reduced investment, asset sales, or restructuring.”

    Latest 424B4final IPO prospectusNegativeBankruptcy / going concernAccounting issueCustomer concentration ·

    GPU cloud and crypto hosting provider pivots toward AI infrastructure; shareholders sell through a direct listing

  • QS QuantumScape

    Exposed“Additional capital will likely be needed, but financing may be unavailable or costly; equity issuance could dilute holders, and registered shares and awards may add selling pressure.”

    Latest 10-QQ3 FY2026Mixed ·

    PowerCo pauses milestone payments during renegotiation, raising uncertainty over QSE-5 industrialization and funding.

    • Revenue—
    • Net income−$84.5MYoY +20.2%
  • RZAI ROZE AI INC.

    Exposed“Additional equity or debt funding may be needed, and financing on acceptable terms is not assured; inability to raise funds could impair growth, debt repayment, or continued operations.”

    Latest 424B4final IPO prospectusNegativeBankruptcy / going concernControlled companyProceeds to insiders or debt ·

    South Korean wireless fire-detection supplier enters a direct listing after FY2025 revenue fell 72.1% Y/Y as construction projects stalled.

  • RZRA Rezera Inc.

    Exposed“Financing may be unavailable or unfavorable; equity can dilute holders, debt can add fixed payments and restrictive covenants, and partnerships may require surrendering valuable rights.”

    Latest S-1/Aamended IPO prospectusBankruptcy / going concernAccounting issueCEO/CFO change ·

    Develops oral anti-inflammatory drugs; IPO funds a pivotal ruvonoflast trial in peripheral artery disease, its first test in these patients.

  • SBE SB Energy, Inc.

    Exposed“The realization of that capacity and backlog is linked to the timely development and commissioning of the generation facilities and to the announced Partnership funding.”

    Latest S-1/Aamended IPO prospectusNegativeRestatementAccounting issueControlled company ·

    Power producer building data centers for SoftBank and OpenAI affiliates seeks to convert ≈$439B of backlog into operating assets

  • SCTX Scribe Therapeutics, Inc.

    Exposed“The company will require significant additional capital for research, trials, manufacturing and potential commercialization.”

    Latest 424B4final IPO prospectusMixedBankruptcy / going concernCustomer concentration ·

    Develops CRISPR medicines to lower cholesterol; $129M all-primary raise funds STX-1150 trials and pipeline development.

  • SEQC SeeQC, Inc.

    Exposed“Funding depends on executing its operating plan and obtaining capital that may be unavailable, costly, dilutive, or subject to restrictive terms.”

    Latest S-1/Aamended IPO prospectusNegativeBankruptcy / going concernAccounting issueCustomer concentration ·

    Quantum-control chip developer with an unfinished platform; commercial products supplied only ≈5% of FY2025 revenue

  • SMR NuScale

    Exposed“continued operating cash burn and reliance on equity-market access remain significant funding and dilution risks.”

    Latest 10-QQ3 FY2026MixedLegal / investigation ·

    Reactor production spending ramps ahead of binding orders as ENTRA1 projects hinge on power deals and RoPower awaits financing.

    • Revenue$281.0KYoY −96.6%
    • Net income−$43.7MYoY +84.0%
  • SO Southern Company

    Exposed“Environmental rules affecting coal combustion residuals and greenhouse-gas emissions, capital-cost recovery, affordability, fuel and labor costs, weather, customer credit and access to capital remain material uncertainties.”

    Latest 8-KEquity raiseDebt financing ·

    Closed a $2.0B corporate-unit offering after full exercise of the over-allotment option, pairing 2029 stock purchases with remarketable senior notes.

  • SPG Simon Property Group

    Exposed“Liquidity is considered sufficient for debt maturities and capital needs through 2026–27, but a prolonged capital-market disruption or weaker operating cash flow could require additional borrowing, reduced capital spending, or other financing.”

    Latest 10-QQ3 FY2026 ·

    Taubman acquisition and higher rents lift property income; depreciation, financing costs and investment losses weigh on earnings.

    • Revenue$1.8BYoY +13.3%
    • Net income$499.8MYoY −17.7%
  • STA Starton Holdings, Inc.

    Exposed“The company expects to need substantial additional capital to advance development, obtain approvals and potentially commercialize products; financing may be unavailable, costly or dilutive.”

    Latest S-1/Aamended IPO prospectusNegativeBankruptcy / going concernAccounting issuePre-revenue ·

    Develops continuous-delivery lenalidomide for blood cancers; offering funds trials but further capital is needed to reach approval

  • TGT Target Corporation

    Exposed“Target also warned that a credit-rating downgrade or adverse market conditions could restrict debt-market access or raise financing costs.”

    Latest 8-KPositiveEarningsGuidance raised ·

    Back-to-school strength and tariff refunds underpin higher FY2026 GAAP and adjusted EPS guidance of $10.65–$11.40.

  • UPST Upstart Holdings

    Exposed“If marketplace funding is insufficient, Upstart may need to hold more loans, accept less favorable financing or reduce originations.”

    Latest 8-KLeadership change ·

    CAO Natalia Mirgorodskaya to leave for another opportunity; CFO Andrea Blankmeyer to serve as interim principal accounting officer

  • VOGX Vogenx, Inc.

    Exposed“It has no committed additional funding source.”

    Latest 424B4final IPO prospectusPositiveBankruptcy / going concernRestatementAccounting issue ·

    Developing oral mizagliflozin for post-bariatric hypoglycemia; $81.3M gross raise funds Phase 2 trials.

  • VRHI Veri MedTech Holdings, Inc.

    Exposed“Continued operations depend on executing the business plan, generating sufficient revenue, and raising capital as needed.”

    Latest S-1/Aamended IPO prospectusNegativeBankruptcy / going concernAccounting issueControlled company ·

    Connects patients with physicians for medical-cannabis certifications; FY2025 revenue fell 34.9% Y/Y as state restrictions hit consultations

  • WBD Warner Bros. DiscoveryDelisted

    Exposed“Management expects cash, operating cash generation and available credit to meet needs for the next 12 months, but substantial debt service, content and sports-rights investment, and credit ratings and leverage constrain financial flexibility.”

    Latest 8-KListing noticeDeal completedDebt financingLeadership change ·

    Paramount Skydance merger closes at $31.02 per WBD share in cash; WBD exits Nasdaq and plans to end SEC reporting.

  • WELL Welltower

    Exposed“Reliance on external funding also exposes the strategy to capital-market availability and financing costs.”

    Latest 8-K ·

    Registers up to ≈1.15M shares for potential Welltower OP redemptions, plus shares for Silver Quebec LP exchanges and Fellowship Grants.

  • WWB WINDWARD BIO GROUP AG

    Exposed“Further capital will be needed; unavailable or unfavorable financing could force delays, reductions, or termination of programs.”

    Latest 424B4final IPO prospectusPositivePre-revenue ·

    Develops long-acting antibodies for asthma and other inflammatory diseases; $175M raise funds trials led by WIN378’s potential twice-yearly dosing

Feedback